

October 22, 2018



VistaGen Therapeutics to Present at Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2018 (GLOBE NEWSWIRE) -- [VistaGen Therapeutics Inc.](#) (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for central nervous system (CNS) diseases and disorders with high unmet need, today announced that Shawn Singh, Chief Executive Officer of VistaGen, will present at the Credit Suisse 27th Annual Healthcare Conference to be held at The Phoenician in Scottsdale, Arizona on Wednesday, November 14, 2018 at 2:15 p.m. MST / 4:15 p.m. EST.

A live audio webcast will be accessible at the time of the presentation on the investor page of VistaGen's website at ir.vistagen.com. A replay of the webcast will be archived on VistaGen's website following the conference.

For more information about the conference, or to schedule a one-on-one meeting with VistaGen's management, please contact your Credit Suisse representative directly, or send an email to brett.weiss@credit-suisse.com.

About VistaGen

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing new generation medicines for multiple CNS diseases and disorders with high unmet need. AV-101, in Phase 2 clinical development, is an oral glutamate receptor modulator (an NMDAR GlyB antagonist) with potential to address shortfalls of current therapies for CNS diseases and disorders such as major depressive disorder, neuropathic pain and suicidal ideation. The U.S. FDA has granted Fast Track designations for development of AV-101 as a treatment for both major depressive disorder and neuropathic pain. PH94B, entering pivotal Phase 3 clinical development, is a novel neuroactive steroid administered as a nasal spray with potential to be the first FDA-approved medication indicated as a rapid-acting, on-demand treatment for social anxiety disorder, a debilitating disorder that affects as many as 15 million adults in the U.S. For more information, please visit www.vistagen.com and connect with VistaGen on [Twitter](#), [LinkedIn](#) and [Facebook](#).

Forward-Looking Statements

This release contains various statements concerning VistaGen's future expectations, plans and prospects, including without limitation, our expectations regarding development and commercialization of our drug candidates, including AV-101 for major depressive disorder,

neuropathic pain and suicidal ideation and PH94B for social anxiety disorder, as well as our intellectual property and commercial protection of our drug candidates, all of which constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements are neither promises nor guarantees of future performance and are subject to a variety of risks and uncertainties, many of which are beyond our control, and may cause actual results to differ materially from those contemplated in these forward-looking statements. Among these risks is the possibility that (i) we may encounter unexpected adverse events in patients in our clinical development of AV-101 or PH94B that cause us to discontinue further development of either drug candidate, (ii) we may not be able to successfully demonstrate the safety and efficacy of AV-101 or PH94B at each stage of clinical development, (iii) success in preclinical studies or in early-stage clinical trials may not be repeated or observed in ongoing or future studies, and ongoing or future preclinical and clinical results may not support further development of, or be sufficient to gain regulatory approval to market AV-101 and/or PH94B, (iv) decisions or actions of regulatory agencies may negatively affect the progress of, and our ability to proceed with, further clinical studies or to obtain marketing approval for our drug candidates, (v) we may not be able to obtain or maintain adequate intellectual property protection and other forms of marketing and data exclusivity for AV-101 or PH94B, (vi) we may not have access to or be able to secure substantial additional capital to support our operations, including clinical development of AV-101 and/or PH94B activities described above; and (vii) we may encounter technical and other unexpected hurdles in the manufacturing and development of AV-101 or PH94B. Certain other risks are more fully discussed in the section entitled "Risk Factors" in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our other filings with the Securities and Exchange Commission (SEC). Our SEC filings are available on the SEC's website at www.sec.gov. In addition, any forward-looking statements represent our views only as of the issuance of this release and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

Company Contact

Mark A. McPartland
VistaGen Therapeutics Inc.
Phone: +1 (650) 577-3600
Email: IR@vistagen.com

Investor Contact

Valter Pinto / Allison Soss
KCSA Strategic Communications
Phone: +1 (212) 896-1254/+1 (212) 896-1267
Email: VistaGen@KCSA.com

Media Contact

Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications
Phone: +1 (212) 896-1241/+1 (508) 843-6428
Email: VistaGen@KCSA.com



Source: VistaGen Therapeutics, Inc.